Combo immunotherapy for advanced melanoma: Two therapies may be better than one
A new metastatic melanoma study suggests that a combination of two immunotherapies may be better than one. One treatment uses a patient’s own T cells modified in the lab to more powerfully recognize and attack tumors; the other treatment, a ‘checkpoint inhibitor,’ releases the brakes on the body’s natural immune system.
Leave a Reply